We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+97.61%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
+$475M
Cap. Flow
-$8.47M
Cap. Flow %
-0.75%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DTIL icon
Precision BioSciences
DTIL
+$8M
2
APLS
Apellis Pharmaceuticals
APLS
+$470K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$273M
$836M 73.8%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.05B
$127M 11.18%
3,504,624
– –
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$63.1M 5.57%
2,444,311
– –
CMPI
4
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$53.6M 4.73%
3,673,374
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$28.1M 2.48%
490,471
-11,113
-2% -$470K
MTCR
6
DELISTED
Metacrine, Inc. Common Stock
MTCR
$24M 2.12%
3,059,123
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$1.39M 0.12%
199,075
– –
DTIL icon
8
Precision BioSciences
DTIL
$188M
– –
-43,273
Closed -$8M

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q4 2020 Portfolio in Review

As of Q4 2020, venBio Partners held 8 positions worth $1.13B, up 72% from $658M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q4 2020 filing shows 1 reduced and 1 closed positions. The largest sale was Precision BioSciences, an estimated $8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q4 2020 reduction was Apellis Pharmaceuticals, cutting an estimated $470K.
  • venBio Partners fully exited Precision BioSciences in Q4 2020, selling an estimated $8M.
  • venBio Partners's ten largest holdings make up 100% of its $1.13B portfolio in Q4 2020.
  • venBio Partners opened 0 new positions and closed 1 in Q4 2020.
  • venBio Partners's portfolio value rose 72% quarter-over-quarter to $1.13B.

Based on venBio Partners's 13F filing for Q4 2020, filed 16 Feb 2021.